Market Overview:
The global SGLT2 inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of type 2 diabetes, rising awareness about SGLT2 inhibitors, and the launch of new products. The global SGLT2 inhibitor market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into dapagliflozin, canagliflozin, empagliflozin, and other. Dapagliflozin held a major share in 2017 owing to its high efficacy and safety profile. On the basis of application, hospital pharmacies accounted for a major share in 2017 owing to increased use in hospitals for better glycemic control among patients with diabetes mellitus (DM). However, retail pharmacies are expected to witness higher growth during the forecast period as these pharmacies offer lower prices for these drugs as compared with hospitals. Geographically speaking North America held a dominant position in 2017 due to factors such as early adoption by key players coupled with rising prevalence rates of DM across countries such as Canada and U.S.
Product Definition:
An SGLT2 inhibitor is a type of medication that blocks the activity of the sodium-glucose cotransporter 2 (SGLT2) enzyme. This enzyme is responsible for reabsorbing glucose from the urine back into the bloodstream, so inhibiting its activity reduces blood sugar levels. SGLT2 inhibitors are used to treat type 2 diabetes mellitus.
Dapagliflozin:
Dapagliflozin is a prescription drug used to treat people with diabetes and certain kidney diseases. It works by increasing the amount of glucose that is transported into the cells instead of being converted into fat or stored as glycogen. Dapagliflozin has been approved by the FDA for use in type 2 diabetes patients who are on hemodialysis and have not been able to maintain well-controlled blood glucose levels during treatment with oral antidiabetics.
Canagliflozin:
Canagliflozin is a medicine used to treat people who have been identified as having diabetes mellitus. It works by increasing the amount of glucose that is transported into the cell instead of being stored in the blood. The increased amount of glucose in cells results in decreased sugar levels in the blood, eventually leading to lower blood pressure and an increase in insulin sensitivity.
Application Insights:
The hospital pharmacies segment dominated the global SGLT2 inhibitor market in 2017. This can be attributed to factors such as an increase in the prevalence of diabetes and rising awareness about SGLT2 inhibitors among hospital pharmacists. Hospital-based pharmacists are more likely to prescribe these drugs owing to their increased availability, which is a major factor driving demand for sglt2 inhibitors from this segment.
Retail pharmacies also accounted for a significant share of the overall revenue due to factors such as high patient awareness regarding access Glucose Lowering Drugs (SLD) through retail channels and availability of different brand formulations through various retail outlets, thereby increasing competition among retailers leading to higher sales compared with other segments.
Regional Analysis:
North America dominated the global SGLT2 inhibitor market in 2017. This is due to the presence of a large number of patients suffering from diabetes and increased healthcare expenditure in this region. In addition, favorable reimbursement policies for these drugs are also expected to drive growth during the forecast period. Asia Pacific is expected to be the fastest-growing regional market over the forecast period owing to high unmet clinical needs coupled with increasing R&D initiatives by various companies for developing novel therapies for diabetes management.
Major players operating in this industry include Amgen Inc.; Takeda Pharmaceuticals North America LLC; Pfizer Inc.; BMS Pharma; Novartis AG; Eli Lilly and Company; Bristol-Myers Squibb Company; Sanofi Paris Nord Est S.A.
Growth Factors:
- Increasing prevalence of type 2 diabetes mellitus (T2DM)
- Growing awareness about the benefits of SGLT2 inhibitors over other antidiabetic therapies
- Rising demand for novel and effective treatments for T2DM
- Technological advancements in the development of SGLT2 inhibitors
- Availability of reimbursement for SGLT2 inhibitors
Scope Of The Report
Report Attributes
Report Details
Report Title
SGLT2 Inhibitor Market Research Report
By Type
Dapagliflozin, Canagliflozin, Empagliflozin, Other
By Application
Hospital Pharmacies, Retail Pharmacies
By Companies
Eli Lilly, Boehringer Ingelheim, Johnson & Johnson, AstraZeneca, Merck, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global SGLT2 Inhibitor Market Report Segments:
The global SGLT2 Inhibitor market is segmented on the basis of:
Types
Dapagliflozin, Canagliflozin, Empagliflozin, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Boehringer Ingelheim
- Johnson & Johnson
- AstraZeneca
- Merck
- Pfizer
Highlights of The SGLT2 Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dapagliflozin
- Canagliflozin
- Empagliflozin
- Other
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the SGLT2 Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
SGLT2 inhibitors are medications that block the action of the SGLT2 enzyme, which helps in the absorption of glucose from the intestine. This class of drugs is used to treat type 2 diabetes and other conditions where blood sugar levels are high.
Some of the major players in the sglt2 inhibitor market are Eli Lilly, Boehringer Ingelheim, Johnson & Johnson, AstraZeneca, Merck, Pfizer.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. SGLT2 Inhibitor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. SGLT2 Inhibitor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. SGLT2 Inhibitor Market - Supply Chain
4.5. Global SGLT2 Inhibitor Market Forecast
4.5.1. SGLT2 Inhibitor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. SGLT2 Inhibitor Market Size (000 Units) and Y-o-Y Growth
4.5.3. SGLT2 Inhibitor Market Absolute $ Opportunity
5. Global SGLT2 Inhibitor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. SGLT2 Inhibitor Market Size and Volume Forecast by Type
5.3.1. Dapagliflozin
5.3.2. Canagliflozin
5.3.3. Empagliflozin
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global SGLT2 Inhibitor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. SGLT2 Inhibitor Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global SGLT2 Inhibitor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. SGLT2 Inhibitor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global SGLT2 Inhibitor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. SGLT2 Inhibitor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global SGLT2 Inhibitor Demand Share Forecast, 2019-2026
9. North America SGLT2 Inhibitor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America SGLT2 Inhibitor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America SGLT2 Inhibitor Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America SGLT2 Inhibitor Market Size and Volume Forecast by Type
9.7.1. Dapagliflozin
9.7.2. Canagliflozin
9.7.3. Empagliflozin
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America SGLT2 Inhibitor Demand Share Forecast, 2019-2026
10. Latin America SGLT2 Inhibitor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America SGLT2 Inhibitor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America SGLT2 Inhibitor Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America SGLT2 Inhibitor Market Size and Volume Forecast by Type
10.7.1. Dapagliflozin
10.7.2. Canagliflozin
10.7.3. Empagliflozin
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America SGLT2 Inhibitor Demand Share Forecast, 2019-2026
11. Europe SGLT2 Inhibitor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe SGLT2 Inhibitor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe SGLT2 Inhibitor Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe SGLT2 Inhibitor Market Size and Volume Forecast by Type
11.7.1. Dapagliflozin
11.7.2. Canagliflozin
11.7.3. Empagliflozin
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe SGLT2 Inhibitor Demand Share, 2019-2026
12. Asia Pacific SGLT2 Inhibitor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific SGLT2 Inhibitor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific SGLT2 Inhibitor Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific SGLT2 Inhibitor Market Size and Volume Forecast by Type
12.7.1. Dapagliflozin
12.7.2. Canagliflozin
12.7.3. Empagliflozin
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific SGLT2 Inhibitor Demand Share, 2019-2026
13. Middle East & Africa SGLT2 Inhibitor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa SGLT2 Inhibitor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa SGLT2 Inhibitor Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa SGLT2 Inhibitor Market Size and Volume Forecast by Type
13.7.1. Dapagliflozin
13.7.2. Canagliflozin
13.7.3. Empagliflozin
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa SGLT2 Inhibitor Demand Share, 2019-2026
14. Competition Landscape
14.1. Global SGLT2 Inhibitor Market: Market Share Analysis
14.2. SGLT2 Inhibitor Distributors and Customers
14.3. SGLT2 Inhibitor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Boehringer Ingelheim
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Johnson & Johnson
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
